Docrates Cancer Center Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2020
NCT04695327
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Docrates Cancer Center

Active Ingredients

Drugs in Phase 1 Trials (2)

avelumab (bavencio) (1 trial)

tilt-123 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenoviridae Infections (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2